Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage IV non-small cell lung cancer that cannot be cured with existing therapeutic regimens~* Measurable disease by CT scan or MRI~  * Tumor must be at least 2 cm for the lymph nodes located in the head, neck, axillary, inguinal or femoral areas and at least 0.5 cm for other areas~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* No hepatic insufficiency~* Bilirubin no greater than 2.5 mg/dL~* SGOT and SGPT no greater than 5 times upper limit of normal~Renal:~* No renal insufficiency~* Creatinine no greater than 2.5 mg/dL~Cardiovascular:~* No chronic heart failure~* No uncontrolled hypertension~Pulmonary:~* No serious lung disease (e.g., severe chronic obstructive pulmonary disease)~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No other serious medical or psychiatric conditions~* No active infection~* No serious malabsorption syndromes~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy (less than 8 weeks if multiple tumors are involved) and recovered~Surgery:~* No prior extensive stomach or intestinal surgery~* Recovered from any prior surgery~Other:~* Prior cytodifferentiating agents allowed~* No prior antineoplaston treatment~* No other concurrent treatment for metastatic lung cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplastons (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).